Quick Facts: Naltrexone Hydrochloride

Primary Uses
Treatment of alcohol use disorder (AUD)
Treatment of opioid use disorder (OUD), to prevent relapse following detoxification

---

Naltrexone hydrochloride is an established medication used to support individuals in recovery from certain substance use disorders. It is approved as a component of a comprehensive management program, which often includes counseling and behavioral therapies.

Therapeutic Domain

The medication has two main indications: the management of alcohol use disorder and the management of opioid use disorder.

• Alcohol Use Disorder: For AUD, naltrexone assists in decreasing heavy drinking and is used to reduce the desire or urge to consume alcohol, supporting abstinence. It is not a substitute for stopping alcohol consumption but acts to modify the physiological response.
• Opioid Use Disorder: For OUD, the medication is administered after the individual has completed medically supervised opioid withdrawal and achieved a period of opioid abstinence. Its primary role is to block the effects of opioids and prevent a return to opioid use. This function is critical for maintenance in the recovery process.

By helping to reduce cravings and blocking the rewarding effects of these substances, naltrexone facilitates sustained recovery and adherence to treatment protocols.

Eligibility Scope

Naltrexone hydrochloride is primarily intended for adults (typically 18 years of age and older) receiving management for alcohol use disorder or opioid use disorder. Eligibility is determined by strict criteria documented in official regulatory labeling.

Contraindications and Restrictions

Use of Naltrexone is contraindicated (absolutely prohibited) for patients receiving opioid analgesics or those with current physiologic opioid dependence, including individuals in acute opioid withdrawal. Further absolute exclusions apply to anyone with acute hepatitis or liver failure, or a known hypersensitivity to the drug or its components.

Specific Population Rules

Prior to treatment initiation for opioid use disorder, an opioid-free interval of at least 7 to 10 days is required by regulators. Use is generally not recommended for pediatric patients under 18 years of age, as safety and efficacy have not been established. Caution is advised for patients with moderate to severe renal or hepatic impairment. For women who are pregnant or breastfeeding, use is conditional, permitted only when the potential benefit outweighs the undetermined risk, as human data are limited.

Interactions with other medicines and products

The primary and most critical interaction for naltrexone hydrochloride is with opioid-containing medicines and substances. As an opioid receptor blocker, naltrexone prevents opioids from producing their expected effects, but co-administration can trigger a sudden and severe withdrawal syndrome in individuals who are physically dependent on opioids. Official regulatory guidance mandates that patients must be opioid-free for a period of 7 to 10 days prior to initiating treatment to prevent this potentially serious reaction.

Patients taking naltrexone must be advised that attempting to overcome the opioid blockade by using large amounts of exogenous opioids is extremely dangerous and can lead to life-threatening overdose or death due to a loss of tolerance.

Other Documented Interactions

The concomitant use of naltrexone with other specific agents requires caution based on official regulatory documentation:

Interacting Product Category	Clinical Significance/Constraint
Opioid Analgesics/Antagonists	Contraindicated in opioid-dependent patients; results in precipitated withdrawal.
Thioridazine (Antipsychotic)	Reported to increase the risk of lethargy and somnolence.
Disulfiram (Alcohol Deterrent)	Not routinely recommended due to a potential for compounded hepatotoxicity.

If opioid analgesia is required for an emergency procedure while taking naltrexone, specialized non-opioid pain management strategies must be implemented. Non-opioid medicines for cough or diarrhea should be used instead of opioid-containing preparations.

The mechanistic action of Naltrexone hydrochloride is centered on its ability to block specific receptor signaling, which results in altered binding affinity and reduced signal transduction in affected pathways.

Opioid Receptor Antagonism

Naltrexone acts within domains involving receptor-mediated signaling by serving as a highly specific, competitive antagonist at the mu (mu), kappa (kappa), and delta (delta) opioid receptors. This mechanism initiates a signaling sequence that suppresses the binding and activation normally caused by endogenous or exogenous opioid ligands.

---

Modulation of Key Homeostatic Pathways

The sustained blockade of these receptors modifies early molecular steps in the affected neural circuits, which alters signaling within pathways associated with heightened physiological responses and baseline or induced signaling activity. Naltrexone engages mechanisms that regulate processes in systems where endogenous opioid activity maintains altered signaling.

---

Influence on Neurotransmitter Systems

Naltrexone affects systems where specific transmitters or mediators dominate, particularly by indirectly impacting downstream release of neurotransmitters like dopamine and GABA (gamma-aminobutyric acid). This pathway adjustment modifies the resulting signal output of the targeted pathways by influencing the signal transmission dynamics within limbic system circuitry.

The administration of naltrexone hydrochloride is characterized by specific routes, doses, and schedules for its use. The medication is available as an oral tablet and as an extended-release injectable suspension (380 mg), which is administered via a deep intramuscular gluteal injection every four weeks or once monthly.

Official Dosing Regimens

The standard adult oral dose for alcohol use disorder (AUD) is 50 mg once daily. For opioid use disorder (OUD), the initiation protocol typically begins with a 25 mg dose on the first day, increasing to 50 mg once daily thereafter, provided there are no signs of withdrawal. Alternative oral schedules, such as a three-times-a-week regimen (e.g., 100 mg on Monday and Wednesday, 150 mg on Friday), are also utilized to support compliance.

Administration Conditions

For the treatment of OUD, an essential procedural condition is the confirmation that the patient has been opioid-free for a minimum of 7 to 10 days prior to starting naltrexone, a measure required to prevent precipitation of acute withdrawal. Oral tablets are typically swallowed with liquid; the extended-release suspension specifies that it must be prepared and administered only by a healthcare professional and that the injection site must be alternated for subsequent doses. Use in pediatric patients under 18 years is not recommended due to insufficient data. If a daily oral dose is missed, the patient should take the next dose at the usual scheduled time and avoid doubling the dose.

Naltrexone hydrochloride: Recent Clinical Evidence

---

Evidence for Use in Alcohol Use Disorder (AUD)

The research exploring Naltrexone for Alcohol Use Disorder (AUD) primarily involves Randomized Controlled Trials (RCTs) structured to compare its use against a placebo. Studies focused on measuring changes in drinking habits, specifically looking at outcomes related to relapse to heavy drinking and the frequency of heavy drinking days. Findings generally describe patterns of lower rates of heavy drinking in the treated groups across the observed time intervals (typically 8 to 16 weeks).

---

Evidence for Use in Opioid Use Disorder (OUD)

Naltrexone was evaluated in research exploring relapse in individuals following detoxification. Studies focused on both the daily oral tablet and the extended-release injectable suspension. RCTs for the injectable formulation reported observations of periods of opioid abstinence compared to controls. However, due to documented challenges with medication adherence to the oral tablet, regulators note its available data are insufficient for reliable assessment outside controlled settings.

---

Research on Long-Term Follow-up and Duration of Effects

Key regulatory trials for both AUD and OUD were designed to observe responses over intermediate-term periods, typically six months to one year. While some follow-up data exists, the long-term effects are not fully established or well-characterized by large RCTs. Limited information means research provides context but not individual predictions regarding the maintenance of observed patterns.

---

Evidence in Special Populations and Subgroups

Research has included populations such as young adults with heavy drinking patterns and patients with co-occurring medical conditions. However, findings have indicated that variability in measured outcomes was higher in certain subgroups (e.g., female cohorts). Data for groups like children or pregnant populations remain insufficient. Results apply only to the populations studied and do not provide definitive guidance for these other groups.

---

What Remains Uncertain About the Research Evidence

Scientific reviews highlight several areas where certainty remains low. A key limitation is the widely documented poor adherence to the daily oral formulation. Additionally, sample sizes were modest or follow-up durations were limited in some studies. Overall, the research highlights areas of inconsistent findings when examining certain demographic subgroups, suggesting that responses may vary across different patient characteristics.

Key Studies & References

1. Chapter 3C: Naltrexone - Medications for Opioid Use Disorder (NIH Bookshelf)
2. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial (Referenced via BU article summarizing key findings)
3. PRESCRIBING INFORMATION | Vivitrol (Extended-Release Naltrexone)

Common questions about Naltrexone hydrochloride (FAQ)

Q: Is there a difference in how the oral tablet and the injectable forms of Naltrexone work?

Both the oral tablet and the extended-release injection contain the same active ingredient, naltrexone, and function the same way by blocking opioid receptors. The extended-release injection is engineered to provide a sustained receptor blockade over approximately one month, which may offer an advantage regarding adherence compared to a daily pill.

Q: Is it normal to feel nauseous or have stomach cramps when starting Naltrexone?

Yes, regulatory documents indicate that nausea is a very common side effect, and abdominal pain or cramps are also common. These reactions are often observed when treatment is first initiated. Official information documents these effects in the drug's safety profile.

Q: Can Naltrexone affect a person's mood or cause increased anxiety?

Official product information states that anxiety is documented as a very common side effect. Additionally, nervousness is listed as a common adverse reaction, and depression is also noted as a possible effect. These are documented in the drug's safety profile.

Q: Is there a link between Naltrexone and feelings of depression or suicidal thoughts?

Regulatory warnings highlight that suicide-related behaviors (including suicidal thoughts) and a significant worsening of depressive symptoms are serious adverse reactions associated with the use of Naltrexone. Official safety information indicates that monitoring for these potential safety concerns is recommended.

Q: Can Naltrexone affect my energy levels?

Yes, official documentation lists effects that relate to energy and sleep. Insomnia (difficulty sleeping) is reported as a very common side effect, while fatigue or unusual tiredness is a common reaction that has been documented in clinical studies.

Q: Can Naltrexone cause changes in my blood pressure or heart rate?

Yes, tachycardia (a fast or pounding heartbeat) is listed as an uncommon side effect. Additionally, official warnings note that increases in blood pressure and heart rate have been observed, especially with combination products containing naltrexone.

Q: Does Naltrexone cause physical withdrawal symptoms if a person stops taking it?

Naltrexone is classified as a pure opioid antagonist and is explicitly non-addictive. Because of this non-addictive nature, stopping the medication does not cause the kind of physical withdrawal symptoms seen when stopping an opioid substance.

Q: Does Naltrexone change a person's sensitivity to opioids after the treatment is stopped?

Yes, regulatory warnings state that once Naltrexone treatment is stopped, a patient may be more sensitive to the effects of opioids than they were before. This increased sensitivity means that if opioids are used, a previously tolerated amount may result in a life-threatening overdose.

Q: Can I take other prescription medications while on Naltrexone?

Regulatory guidance emphasizes the importance of informing a healthcare provider about all medications. Critical interactions exist with opioid-containing products. Caution is specifically advised with agents such as the antipsychotic Thioridazine or the alcohol deterrent Disulfiram due to documented risks.

Q: Does Naltrexone interact with over-the-counter pain relievers like acetaminophen or ibuprofen?

Regulatory documents do not list specific interactions with common non-opioid pain relievers such as acetaminophen or ibuprofen. However, this is relevant for any medication or supplement that may affect liver function, given Naltrexone's risk profile regarding liver injury (hepatotoxicity).

Q: Does Naltrexone interact with cough syrups that contain opioids?

Official safety information mandates that patients taking Naltrexone must not use any type of opioid-containing medicines, which includes certain cough, cold, or anti-diarrhea preparations. This restriction prevents the risk of precipitating severe opioid withdrawal or overdose.

Q: Does Naltrexone interact with any common herbal supplements?

Regulatory documents advise patients to inform their healthcare provider about all medications, supplements, herbs, and vitamins they are taking. Interactions are possible, particularly with supplements that could affect liver function, which is a known safety consideration with Naltrexone.

Q: What is the typical duration of treatment with Naltrexone?

Clinical trials reviewed by regulatory bodies observed the effects of the medication over intermediate-term periods, often ranging from six months to one year. The determination of the appropriate duration of treatment is an individual decision made by a healthcare provider.

Q: How quickly does Naltrexone begin to work after the first dose is taken?

For the oral tablet, official pharmacokinetic data indicate that the active drug and its metabolite are rapidly absorbed, reaching peak concentrations in the bloodstream in approximately one hour. This quick absorption establishes the necessary opioid receptor blockade.

Q: What should I tell a doctor or dentist before a procedure if I am taking Naltrexone?

Regulatory patient counseling advice strongly recommends informing all medical healthcare providers, dentists, and pharmacists that Naltrexone is being taken. Official guidance suggests carrying identification that states the patient is taking Naltrexone in case of an emergency.

Q: Does Naltrexone help reduce or eliminate cravings for alcohol or opioids?

Yes, according to official information, Naltrexone’s core mechanism of blocking opioid receptors is reported to help reduce or suppress the associated urges and cravings for alcohol and opioids. It is intended to be a supportive part of comprehensive treatment.

Q: Does Naltrexone prevent a person from enjoying natural feelings of pleasure or satisfaction from everyday life?

Naltrexone acts as a competitive antagonist primarily at the mu-opioid receptor, which specifically blocks the euphoric response caused by certain substances. Official documents do not report that the drug blocks feelings of satisfaction that are not mediated by the opioid receptors.

Q: What happens to the body if a person consumes alcohol while taking Naltrexone?

When taking Naltrexone, the euphoric and rewarding feelings typically associated with consuming alcohol are blocked or reduced. However, regulatory information is clear that Naltrexone will not prevent a person from experiencing impairment (such as poor coordination or slowed reaction time) from drinking alcohol.

Q: Are weight loss or appetite changes possible side effects of Naltrexone?

Official safety data confirms that decreased appetite is listed as a common adverse reaction in the drug’s profile. Additionally, changes described as weight decreased and anorexia have also been reported from clinical studies.

How to Store and Dispose of Naltrexone Hydrochloride

Storage requirements for naltrexone hydrochloride are determined by the pharmaceutical form to ensure product stability and integrity.

Storage Conditions

Form	Temperature Requirement	Additional Protection
Oral Tablets	Store at 25 C (77 F), with permitted excursions to 15 C to 30 C.	Must be stored in a tight, light-resistant container.
Injectable Suspension	Store in the refrigerator at 2 C to 8 C.	Must not be frozen. If removed from refrigeration, it must not exceed 25 C for more than 7 days.

All naltrexone products must be stored to keep out of the reach of children. The oral form requires a child-resistant closure.

Disposal

Unused or expired product must be disposed of in accordance with local regulations. Naltrexone is not listed by the FDA as a medicine recommended for disposal by flushing. For the injectable suspension, healthcare providers must discard materials, including needles and syringes, as pharmaceutical waste into an approved sharps container.